SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (28978)6/27/1999 5:27:00 PM
From: J Stone  Respond to of 32384
 
Cheryl,

Thanks for the detailed info. It explains quite a bit.

Jeff



To: Cheryl Galt who wrote (28978)6/29/1999 3:00:00 PM
From: Henry Niman  Respond to of 32384
 
Targretin was granted Orphan Drug Status on June 18, 1999:

Generic Name: Bexarotene

Trade Name: Targretin

Orphan Indication: Treatment of cutaneous T-cell lymphoma.

Sponsor: Ligand Pharmaceuticals, Inc.

Address: San Diego, CA

Contact: Dr. Howard Holden

Phone: (619) 550-7600

Fax: (619) 550-1827

Designation Date: 06/18/1999


verity.fda.gov


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News